The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes

Open Access

Peer-reviewed

Research Article

Sam Tsz Wai Cheng,

Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong
⨯
Lihua Chen,

Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong
⨯
Stephen Yu Ting Li,

Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong
⨯
Eric Mayoux,

Affiliation Boehringer-Ingelheim Pharma GmbH & Co KG, Biberach, Germany
⨯
Po Sing Leung

* E-mail: psleung@cuhk.edu.hk

Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong
⨯

Reader Comments (0)

Insulin
Is the Subject Area "Insulin" applicable to this article?

Thanks for your feedback.
Glucose
Is the Subject Area "Glucose" applicable to this article?

Thanks for your feedback.
Blood sugar
Is the Subject Area "Blood sugar" applicable to this article?

Thanks for your feedback.
Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Homeostasis
Is the Subject Area "Homeostasis" applicable to this article?

Thanks for your feedback.
Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.